This post was authored by Mike Madarasz of the Institute for International Research. You can follow him on Twitter at @MikeMadarasz
In an effort to increase efficiency and streamline
development of effective cancer therapies as well hold down costs associated
with conducting clinical trials, drug developers have increased their
investment in clinical biomarker research.
Specifically, there has been an increase in the use of pharmagenomic
(PGX) biomarkers to either select or stratify patients. Citeline recently published a white paper outlining some of the
major impacts in oncology—some of which are explained in the charts below.
The increase in oncology trials selecting
or stratifying by PGBX Biomarkers
The percentage of trials in this category has
more than doubled since 2002
Breakdown of countries in PGX trials
The U.S. accounts for nearly 30% of these
trials with Japan being the next closest at almost 15%.
Top sponsors using PGX biomarkers to
select/stratify patients
The National Cancer Institute comes
out as the top sponsor both in the relative sense and in number of PGX trials.
You can hear more from top industry thought leaders. Check out the Biorepositories and Sample Management
Conference.
September 8-10, 2015 | Boston, MA
Register here. Discount code:
XP1998BLOG
Free Webinar-Breadth and Depth: Oh, What a Data-Rich Biorepository Can Do for Your Research!
DATE: April 30, 2014, 2:00 PM - 3:00PM EST
Register here
Free Webinar-Breadth and Depth: Oh, What a Data-Rich Biorepository Can Do for Your Research!
DATE: April 30, 2014, 2:00 PM - 3:00PM EST
Register here
Discount Code: XP1998BLOG
|
Share this article with your social network, just click below to share now!
|
|
|
